🏛️ Verified NIH Record • Updated 2026-06-17

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer (NCT07662031)

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Washington University School of Medicine

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (15 items) and avoid the listed exclusions (20 items).

Location: Washington University School of Medicine — St Louis, Missouri

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Patients with MSI-H status.
  • Intact primary tumor that has not been resected.
  • More than one line of prior therapy for advanced or metastatic CRC. \*If FOLFIRI/FOLFOXIRI was given in the first line, it must have been completed ≥ 6 months before study start date.
  • Surgery or major procedure, or systemic anticancer therapy within 4 weeks prior to C1D1.
  • Radiation therapy within 2 weeks prior to C1D1.
  • Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • Receipt of any other investigational agents within 4 weeks prior to C1D1, with exception of investigational imaging agents.
  • Patients with untreated brain metastases. Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression.
  • Prior history of diseases/conditions that elevates the patient's risk of hemorrhage, such as a bleeding diatheses, history of prior bowel perforation, or clinically significant active bleeding (i.e. hemoptysis larger than a tablespoon within 3 weeks prior to C1D1).
  • Recent history of paracentesis (within 3 weeks prior to C1D1) or current indwelling catheter.
  • A history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Tovecimig (i.e. humanized/human monoclonal antibody drugs), FOFLIRI, or other agents used in the study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Washington University School of Medicine — St Louis, Missouri

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗